What is ImpriMed?
Founded in 2017 and headquartered in Palo Alto, California, ImpriMed operates at the intersection of veterinary medicine and advanced data analytics. The company specializes in collecting systemic information directly from the live cancer cells of pet patients, providing veterinarians with actionable insights to tailor chemotherapy and treatment protocols. This data-driven methodology significantly improves clinical outcomes by moving away from one-size-fits-all treatment models toward highly personalized, evidence-based care. As the veterinary oncology market continues to evolve, ImpriMed's proprietary platform serves as a vital tool for clinics seeking to enhance the quality of life for pets diagnosed with complex malignancies.
How much funding has ImpriMed raised?
ImpriMed has raised a total of $31M across 2 funding rounds:
Other Financing Round
$8M
Series A
$23M
Other Financing Round (2021): $8M with participation from Primer Sazze Partners, HG Initiative, Draper Dragon, BonAngels, Translink Investment, Murex Partners, E.S. Investments, Draper Associates, and Futureplay
Series A (2023): $23M led by Samyang Chemical Group (삼양화학그룹, Byucksan, Murex Partners, and SK Telecom
Key Investors in ImpriMed
Samyang Chemical Group
Samyang Chemical Group is a diversified conglomerate with interests in chemicals, distribution, and IT, actively fostering innovation through its DREAUM startup investment initiative.
Byucksan
Byucksan is a prominent construction materials firm that supports industrial innovation and sustainable development through strategic capital allocation.
SK Telecom
SK Telecom is a global leader in telecommunications and AI-driven digital infrastructure, focusing on transformative technologies that enhance connectivity and industry performance.
What's next for ImpriMed?
With the successful closure of its latest financing round, ImpriMed is well-positioned to scale its operations and deepen its integration within the global veterinary healthcare ecosystem. The strategic backing from a diverse group of investors provides the necessary resources to enhance its diagnostic platform and potentially explore new therapeutic avenues. Moving forward, the company is expected to focus on increasing its clinical footprint, refining its predictive algorithms, and strengthening its partnerships with veterinary oncology specialists. This growth trajectory suggests a long-term commitment to establishing a new standard of care in veterinary medicine, ultimately bridging the gap between human-grade precision oncology and pet health services.
See full ImpriMed company page
